mGluR2

Metabotropic glutamate receptor 2 (mGluR2) functions as a presynaptic inhibitory receptor regulating glutamatergic neurotransmission through Galpha inhibitory subunits^[1]. Mechanistically, mGluR2 modulates synaptic plasticity at hippocampal mossy fiber-CA3 synapses, mediating transient suppression of transmission, long-term depression (LTD), and inhibition of long-term potentiation (LTP)^[1]. Compared with its closely related isoform mGluR3, mGluR2 exhibits distinct presynaptic localization and does not directly promote neural progenitor proliferation via ERK1/2 or JNK2 signaling^[2]. In disease models, mGluR2 contributes to fear extinction in the lateral amygdala through long-term weakening of presynaptic release probability^[3], while peripheral mGluR2 activation reduces prostaglandin E2-induced nociceptive sensitization^[4]. In COVID-19 patients, anti-mGluR2 autoantibodies have been identified, indicating immune system cross-reactivity and potential neurological implications^[5]. Pharmacologically, mGluR2-selective agonists, such as LY395756, modulate NMDA receptor expression and function, whereas positive allosteric modulators like (+)-TFMPIP selectively attenuate stress-induced phasic glutamate release without affecting tonic levels^[6][7]. These findings highlight mGluR2 as a target for studies of synaptic plasticity, neuropsychiatric disorders, inflammatory pain, and allosteric modulation in experimental models.